支持Zn-Fe主电池的胃中受控释放气,用于改善与肥胖相关的2型糖尿病患者的胰岛素抵抗
Boyan Liu1, Peixun Lv1,2, Xiaoyi Zhang1
1Key Laboratory of Major Diseases and Hydrogen Medical Translational Applications in Universities of Shandong Province & Key Laboratory of Hydrogen Biomedical Research of Health Commission of Shandong Province, Taishan Institute for Hydrogen Biomedical Research, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, 271000, China.
Bioactive materials
|December 4, 2023
概括
一种新的铁微型/纳米结构可以控制气的释放,有效地改善胰岛素耐药性并减少肥胖相关的2型糖尿病模型中的炎症,没有观察到毒性.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 代谢疾病 代谢疾病
背景情况:
- 与肥胖相关的2型糖尿病 (T2D) 涉及慢性炎症和胰岛素抵抗 (IR).
- 分子 (H2) 显示了治疗潜力,但在传统的输送中面临生物可用性挑战.
- 现有的H2施用方法缺乏足够的剂量和持续时间来有效地治疗IR组织.
研究的目的:
- 开发一种可控释放的战略,以提高H2的生物可用性和IR的治疗效果.
- 研究一种-铁 (Zn-Fe) 微/纳米结构,用于定时的H2生成,与胃排空相匹配.
- 在与肥胖相关的T2D小鼠模型中评估这种新H2输送系统的疗效和安全性.
主要方法:
- 构建Zn-Fe主电池微/纳米结构,可通过调整Fe/Zn比率来调整H2释放率.
- 将Zn-Fe结构口服给瘦素缺乏 (ob/ob) 的小鼠,这是与肥胖相关的T2D的模型.
- 监测H2生成时间,组织积累和对IR和全身炎症的治疗作用.
主要成果:
- Zn-Fe结构 (Fe/Zn比为1:100) 在胃酸中释放了H2大约3小时,与小鼠的胃空化保持一致.
- 在体内监测证实了与富含H2的水相比,在关键的IR组织 (肝脏,脂肪,肌肉) 中高剂量,长时间的H2积累.
- 口服 (200毫克/公斤) 显著改善了IR,减少了ob/ob小鼠的全身炎症,并且没有明显的毒性.
结论:
- 开发的Zn-Fe微/纳米结构提供了一种新的,可控的H2释放策略,以提高治疗疗效.
- 这种方法有效地解决了传统H2输送的局限性,用于治疗与肥胖相关的T2D和IR.
- 该战略为代谢疾病中的疗提供了一个安全而有前途的新途径.
相关概念视频
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Hypoglycemia and Glucagon
272
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
272
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K


